INTERVIEW WITH ARJUN BALAR
A New Era In Systemic Therapies, Pembrolizumab for High Risk Non-Muscle Invasive BCG-Refractory Patients

INTERVIEW WITH CHRISTOPHER LOGOTHETIS
Understanding Differences in Outcomes of Men with Prostate Cancer Based on Race and Ethnicity

INTERVIEW WITH HOWARD SOULE
Advances in PSMA-directed Radionuclide Therapy

INTERVIEW WITH COLIN PRITCHARD
Monoallelic vs Biallelic BRCA2 Alterations, PARP Inhibitors in Prostate Cancer

Videos
State-of-the-industry video lectures by leading urology experts
Featured Videos

Long-Term Safety and Curvature Deformity Characterization in Patients Previously Treated With Collagenase Clostridium Histolyticum for Peyronie's Disease.

To assess the long-term safety and immunogenicity profile of collagenase clostridium histolyticum (CCH) and characterize penile curvature deformity over time in patients previously treated for Peyronie's disease (PD).

This phase 4 study included men who received CCH in either 12-month, double-blind, placebo-controlled clinical trials (IMPRESS I/II), or one of two 9-month open-label studies. Eligible patients received no additional CCH treatment and were followed once yearly for up to 5 years to assess PD clinical symptoms, patient-reported outcomes, and safety.

Of 280 patients enrolled, 204 (73%) completed the study. At baseline, patients (n=247) had already experienced mean penile curvature decrease from 51.8±15.0° to 31.0±16.1° (improvement of 20.9±16.2° or 39.5%). At Year 5 (n=180), despite no additional treatment, there was an additional 9.1% improvement in mean penile curvature compared with Reference data (4.3±13.4°; 95% CI, 2.3-6.2°; p<0.02). At baseline, patients (n=183) experienced mean Peyronie's Disease Questionnaire (PDQ) bother domain score improvement from 6.5±3.5 to 3.4±3.3. At Year 5, there was additional score improvement to 2.4±2.9 (p=0.0003). Adverse events (AEs) were reported in 17.5% (49/280) of patients, but no AEs were considered treatment-related. No long-term safety issues were identified up to 5 years posttreatment. Long-term immunogenicity profiling showed a decreasing trend in the number of anti-AUX-I and anti-AUX-II seropositive patients at Years 4 and 5 after CCH treatment.

Most CCH-treated patients continued to have penile curvature and PDQ domain score improvements through Year 5 without additional CCH treatment, and no additional safety signals were identified.

The Journal of urology. 2020 Jan 10 [Epub ahead of print]

Irwin Goldstein, Larry I Lipshultz, Michael McLane, Yiqun Hu, Qinfang Xiang, Genzhou Liu, Saji Vijayan, Martin K Gelbard

Alvarado Hospital, San Diego, California., Baylor College of Medicine, Houston, Texas., Endo Pharmaceuticals Inc., Malvern, Pennsylvania., Urology Associates Medical Group, Burbank, California.

Conference Coverage
 
Recent data from conferences worldwide
  • 2019 Annual Meeting / December 4-6 / Washington, DC
  • 2019 Annual Congress / October 17 - October 20 / Athens, Greece
  • 2019 Annual Meeting / October 3 - October 5 / Aarhus, Denmark
  • 2019 Annual Congress / September 27 - October 1 / Barcelona, Spain
  • 2019 Biennial Meeting / August 29-31 / Basel, Switzerland
  • 2019 Think Tank / August 8-10 / Washington, DC
  • 2019 Annual Meeting / May 31 - June 6 / Chicago, IL
  • 2019 Annual Meeting / May 3-6 / Chicago, IL
Journals
Publications focusing on urologic cancer treatments through original manuscripts